Yaşamı Tehdit Eden Sistemik Lupus Eritematozus Vakasında Rituksimab Tedavisi

Öz

Sistemik Lupus Eritematozus, heterojen otoinflamatuar bir hastalıktır. Patofizyolojisinde genetik nedenlerin yanında çevresel multifaktöryel etkenler suçlanmıştır. B hücrelerinin aşırı aktivasyonunun lupus patofizyolojisin- de önemli rol oynadığı gösterilmiştir. Çocuklarda tedavi- sinde steroidler ve immunsupresif ajanlar kullanılmakta- dır. Rituksimab, B lenfositlerin CD20 antijenlerine karşı geliştirilen bir biyolojik ajandır. B hücrelerine bağlı oto- inflamatuvar hastalıklarda etkin olduğu gösterilmiştir. Bu makalede, ciddi komplikasyonları olan ve diğer immun- supresif tedavilere yanıt vermeyen sistemik lupus eritema- tozus tanılı çocuk vakasında rituksimab tedavisi deneyimi paylaşılacaktır

Anahtar Kelimeler

• Sistemik Lupus Eritematozus,rituksimab,immunsupresif ajanlar

Rituximab Treatment of A Case with Life-Threatening Systemic Lupus Erythematosus

Öz

Systemic Lupus Erythematosus SLE is a heterogeneous autoinflammatory disease. Genetic and environmental multi- factorial agents have been implicated in its pathophysiology. Hyperactivation of B cells has been demonstrated to play a central role in SLE pathophysiology. Steroids and immuno- suppressive agents are administered in the treatment of child- ren. Rituximab is a biologic agent developed against CD20 antigens of B cells. It has been shown that rituximab is effec- tive in B cell-dependent autoinflammatory diseases. In this paper, we will share our experience about rituximab treatment of a pediatric case with the diagnosis of lupus erythematosus with severe complications and unresponsive to other immuno- suppressive therapies

Anahtar Kelimeler

• Systemic Lupus Erythematosus SLE,rituximab,immunosuppressive agents

Kaynakça

1. mir S, keskinoğlu a. Çocukluk çağı lupus nefriti izle- minde anti-dsDNA düzeyi. Ege Tıp Dergisi 2003;42(1):19-24.
2. makay B, ünsal E. Jüvenil sistemik lupus eritemato- zus. Klinik Gelişim 2006;19(1):24-33.
3. Livingston B, Bonner a, Pope J. Differences in clini- cal manifestations between childhood-onset lupus and adult-onset lupus: a meta-analysis. Lupus 2011;20(13): 1345-55. http://dx.doi.org/10.1177/0961203311416694
4. Vachvanichsanong P, mcneil E. Pediatric lupus neph- ritis: more options, more chances? Lupus 2013;22(6): 545-53. http://dx.doi.org/10.1177/0961203313485490
5. rovin Bh, Furie r, Latinis k, Looney rJ, Fervenza FC, Sanchez-Guerrero J et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum 2012;64(4):1215-26. http://dx.doi.org/10.1002/art.34359
6. Pinto LF, Velásquez CJ, Prieto C, mestra L, Forero E, márquez Jd. Rituximab induces a rapid and susta- ined remission in Colombian patients with severe and refractory systemic lupus erythematosus. Lupus 2011;20(11):1219-26. http://dx.doi.org/10.1177/0961203311409273
7. davies rJ, Sangle Sr, Jordan nP, aslam L, Lewis mJ, Wedgwood r et al. Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis. Lupus 2013; 22(6):574-82. http://dx.doi.org/10.1177/0961203313483376
8. Trachana m, koutsonikoli a, Farmaki E, Printza n, Tzimouli V, Papachristou F. Safety and efficacy of rituximab in refractory pediatric systemic lupus erythe- matosus nephritis: a single-center experience of Northern Greece. Rheumatol Int 2013;33(3):809-13. http://dx.doi.org/10.1007/s00296-011-2239-6

9. Willems m, haddad E, niaudet P, koné-Paut I, Bensman a, Cochat P et al. Rituximab therapy for childhood-onset systemic lupus erythematosus. J Pediatr 2006;148(5):623-27. http://dx.doi.org/10.1016/j.jpeds.2006.01.041
10. Lehman TJ, Singh C, ramanathan a, alperin r, adams a, Barinstein L et al. Prolonged improvement of childhood onset systemic lupus erythematosus follo- wing systematic administration of rituximab and cyclophosphamide. Pediatr Rheumatol Online J 2014; 12:3. http://dx.doi.org/10.1186/1546-0096-12-3